CoChat

Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection

Open access
Vibholm, Line, Schleimann, Mariane H., Højen, Jesper F., Benfield, Thomas, Offersen, Rasmus, Rasmussen, Katrine, Olesen, Rikke, Dige, Anders, Agnholt, Jørgen, Grau, Judith, Buzon, Maria, Wittig, Burghardt, Lichterfeld, Mathias, Petersen, Andreas Munk, Deng, Xutao, Abdel-Mohsen, Mohamed, Pillai, Satish K., Rutsaert, Sofie, Trypsteen, Wim, De Spiegelaere, Ward, Vandekerchove, Linos, Østergaard, Lars, Rasmussen, Thomas A., Denton, Paul W., Tolstrup, Martin, Søgaard, Ole S. · 2017 · Clinical Infectious Diseases
Cited by 147

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

BACKGROUND.: Treatment with latency reversing agents (LRAs) enhances human immunodeficiency virus type 1 (HIV-1) transcription in vivo but leads to only modest reductions in the size of the reservoir, possibly due to insufficient immune-mediated elimination of infected cells. We hypothesized that a single drug molecule-a novel Toll-like receptor 9 (TLR9) agonist, MGN1703-could function as an enhancer of innate immunity and an LRA in vivo. METHODS.: We conducted a single-arm, open-label study in which 15 virologically suppressed HIV-1-infected individuals on antiretroviral therapy received 60 mg MGN1703 subcutaneously twice weekly for 4 weeks. We characterized plasmacytoid dendritic cell, natural killer (NK), and T-cell activation using flow cytometry on baseline and after 4 weeks of treatment. HIV-1 transcription was quantified by measuring plasma HIV-1 RNA during MGN1703 administration. RESULTS.: In accordance with the cell type-specific expression of TLR9, MGN1703 treatment led to pronounced activation of plasmacytoid dendritic cells and substantial increases in plasma interferon-α2 levels (P < .0001). Consistently, transcription of interferon-stimulated genes (eg, OAS1, ISG15, Mx1; each P < .0001) were upregulated in CD4+ T cells as demonstrated by RNA sequencing. Further, proportions of activated cytotoxic NK cells and CD8+ T cells increased significantly during MGN1703 dosing, suggesting an enhancement of cellular immune responses. In 6 of 15 participants, plasma HIV-1 RNA increased from <20 copies/mL to >1500 copies/mL (range, 21-1571 copies/mL) during treatment. CONCLUSIONS.: TLR9 agonist treatment in HIV infection has a dual potential by increasing HIV-1 transcription and enhancing cytotoxic NK cell activation, both of which are key outcomes in HIV-1 eradication therapy. CLINICAL TRIALS REGISTRATION.: NCT02443935.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/cix201

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 147

Metadata

Authors
Vibholm, L., Schleimann, M. H., Højen, J. F., Benfield, T., Offersen, R., Rasmussen, K., Olesen, R., Dige, A., Agnholt, J., Grau, J., Buzon, M., Wittig, B., Lichterfeld, M., Petersen, A. M., Deng, X., Abdel-Mohsen, M., Pillai, S. K., Rutsaert, S., Trypsteen, W., De Spiegelaere, W., Vandekerchove, L., Østergaard, L., Rasmussen, T. A., Denton, P. W., Tolstrup, M., & Søgaard, O. S.
Venue
Clinical Infectious Diseases
Published
2017-03-09
Volume
64
Issue
12
Pages
1686-1695
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2593700719
Cited by
147
References
5
FWCI
8.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection. https://app.cochat.ai/papers/10.1093/cid/cix201
The paper
Vibholm, L., Schleimann, M. H., Højen, J. F., Benfield, T., Offersen, R., Rasmussen, K., Olesen, R., Dige, A., Agnholt, J., Grau, J., Buzon, M., Wittig, B., Lichterfeld, M., Petersen, A. M., Deng, X., Abdel-Mohsen, M., Pillai, S. K., Rutsaert, S., Trypsteen, W., . . . Søgaard, O. S. (2017). Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection. Clinical Infectious Diseases. https://doi.org/10.1093/cid/cix201

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.